Eyenovia, Inc.

$7.56+3.99%(+$0.29)
TickerSpark Score
64/100
Mixed
53
Valuation
40
Profitability
100
Growth
76
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EYEN research report →

52-Week Range5% of range
Low $0.85
Current $7.56
High $124.80

Companywww.eyenovia.com

Eyenovia, Inc. , a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.

CEO
Michael M. Rowe
IPO
2018
Employees
13
HQ
New York City, NY, US

Price Chart

-89.56% · this period
$41.45$21.19$0.92Nov 01May 07Nov 17

Valuation

Market Cap
$38.59M
P/E
-1.22
P/S
18.09
P/B
0.69
EV/EBITDA
-1.83
Div Yield
0.00%

Profitability

Gross Margin
63.68%
Op Margin
-2012.57%
Net Margin
-3163.01%
ROE
-63.54%
ROIC
-31.07%

Growth & Income

Revenue
$813.46M · 1418650.87%
Net Income
$-46,999,218,000 · -94241.02%
EPS
$0.00 · 100.00%
Op Income
$-46,721,061
FCF YoY
-48674.69%

Performance & Tape

52W High
$124.80
52W Low
$0.85
50D MA
$4.53
200D MA
$9.74
Beta
1.00
Avg Volume
4.65M

Get TickerSpark's AI analysis on EYEN

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 21, 25Avenue Capital Management II, L.P.other5,952,381
Jan 31, 25Avenue Capital Management II, L.P.other0
Nov 22, 22Avenue Capital Management II, L.P.other2,327,747
Apr 21, 25Strahlman Ellen Rother3,000
Apr 21, 25Palanki Ramother3,000
Apr 21, 25MATHER CHARLES E IVother8,000
Apr 21, 25JACOBSON RACHELother3,000
Apr 21, 25Ianchulev Tsontchoother5,000
Apr 21, 25GELTZEILER MICHAEL Sother5,000
Apr 21, 25Strahlman Ellen Rother3,000

Our EYEN Coverage

We haven't published any research on EYEN yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate EYEN Report →

Similar Companies